Verification of WFA-Sialylated MUC1 as a Sensitive Biliary Biomarker for Human Biliary Tract Cancer

[1]  A. Kuno,et al.  Assessment of tumor characteristics based on glycoform analysis of membrane-tethered MUC1. , 2017, Laboratory investigation; a journal of technical methods and pathology.

[2]  M. Kurosaki,et al.  Serum Wisteria Floribunda Agglutinin-Positive Sialylated Mucin 1 as a Marker of Progenitor/Biliary Features in Hepatocellular Carcinoma , 2017, Scientific Reports.

[3]  T. Kaneko,et al.  Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer , 2017, International journal of molecular sciences.

[4]  Xiao‐Yu Yin,et al.  Serum CYFRA 21-1 in Biliary Tract Cancers: A Reliable Biomarker for Gallbladder Carcinoma and Intrahepatic Cholangiocarcinoma , 2015, Digestive Diseases and Sciences.

[5]  M. Nagino,et al.  Review of hepatopancreatoduodenectomy for biliary cancer: an extended radical approach of Japanese origin , 2014, Journal of hepato-biliary-pancreatic sciences.

[6]  M. Nagino,et al.  Randomized controlled trial on timing and number of sampling for bile aspiration cytology , 2014, Journal of hepato-biliary-pancreatic sciences.

[7]  O. Kocaman,et al.  Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions. , 2014, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.

[8]  K. Hatakeyama,et al.  Clinicopathological Features of Benign Biliary Strictures Masquerading as Biliary Malignancy , 2012, The American surgeon.

[9]  M. Nagino,et al.  Prospective study of biliary cytology in suspected perihilar cholangiocarcinoma , 2011, The British journal of surgery.

[10]  Masakazu Yamamoto,et al.  Wisteria floribunda agglutinin‐positive mucin 1 is a sensitive biliary marker for human cholangiocarcinoma , 2010, Hepatology.

[11]  T. Fujita,et al.  Incidence, clinical presentation and pathological features of benign sclerosing cholangitis of unknown origin masquerading as biliary carcinoma , 2010, Journal of hepato-biliary-pancreatic sciences.

[12]  M. Gonen,et al.  Differential diagnosis of proximal biliary obstruction. , 2006, Surgery.

[13]  M. D'Angelica,et al.  Clinical and pathologic features of proximal biliary strictures masquerading as hilar cholangiocarcinoma. , 2005, Journal of the American College of Surgeons.

[14]  Min Lu,et al.  Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA. , 2004, World journal of gastroenterology.

[15]  M. Balk,et al.  Are serum and biliary carcinoembryonic antigen and carbohydrate antigen19-9 determinations reliable for differentiation between benign and malignant biliary disease? , 2003, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.

[16]  T. Irimura,et al.  The epitope recognized by the unique anti-MUC1 monoclonal antibody MY.1E12 involves sialyl alpha 2-3galactosyl beta 1-3N-acetylgalactosaminide linked to a distinct threonine residue in the MUC1 tandem repeat. , 2002, Journal of immunological methods.

[17]  T. V. van Gulik,et al.  Incidence of benign lesions in patients resected for suspicious hilar obstruction , 2001, The British journal of surgery.

[18]  R. Edwards,et al.  Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. , 2000, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[19]  S. Kawasaki,et al.  Proximal bile duct stricture disguised as malignant neoplasm. , 1999, Surgery.

[20]  S. Hirohashi,et al.  Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients. , 1998, Cancer research.